Every 10-Q that Autonomix Medical, Inc. (AMIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMIX filings page.
Autonomix Medical, Inc. is a development-stage medical device company with no revenues, focused on catheter-based neural sensing and RF ablation for pain associated with pancreatic cancer and other nerve-related disorders. For the three months ended June 30, 2026, it reported a net loss of $2.7 million, compared with $3.3 million a year earlier, as operating expenses declined 19% to $2.8 million driven mainly by lower stock-based compensation and general and administrative costs.
As of June 30, 2026, Autonomix had cash of $3.5 million, total assets of $7.6 million, working capital of $3.1 million and an accumulated deficit of $69.8 million. Net cash used in operating activities was $3.5 million for the quarter. Management estimates existing cash, together with proceeds from a July 2026 warrant exercise that raised approximately $2.6 million, will fund operations into but not beyond the first calendar quarter of 2027 and expects additional financing needs of about $25–$30 million to reach commercialization of its first indication. These conditions raise substantial doubt about its ability to continue as a going concern.
During the period, the company effected a 1-for-21 reverse stock split and subsequently regained compliance with Nasdaq’s $1.00 bid-price requirement. Capital structure is complex, with 512,394 potentially dilutive securities outstanding. Management reports ongoing material weaknesses in internal control over financial reporting, including lack of segregation of duties and technology control issues, and is adding personnel and consultants to improve controls.
Autonomix Medical, Inc. reported another quarter as a pre-revenue, clinical-stage medical device company, advancing a catheter-based platform that combines nerve signal sensing with RF ablation to treat peripheral nervous system disorders, initially focused on pancreatic cancer pain and other visceral cancers.
For the nine months ended December 31, 2025, the company recorded a net loss of $14.0 million, up from $8.2 million a year earlier, driven by higher research and development spending of $5.7 million and general and administrative costs of $8.6 million. Cash used in operating activities was $9.4 million, leaving cash of $9.9 million and working capital of $8.5 million at period end.
Autonomix strengthened its balance sheet through equity financing, including at-the-market issuances, a Lincoln Park equity line, warrant inducement transactions and a November 2025 private placement that generated about $5.0 million in gross proceeds. However, the company had an accumulated deficit of $64.4 million and disclosed substantial doubt about its ability to continue as a going concern, estimating its current cash will fund operations into but not beyond the third calendar quarter of 2026 and that approximately $30–$36 million of additional financing will be needed to reach commercialization of its first indication.
Autonomix Medical (AMIX) reported Q2 FY2026 results highlighting higher operating spend and ongoing losses. The company posted a net loss of $7.5 million for the quarter and $10.8 million for the six months ended September 30, 2025, driven by general and administrative expenses of $5.2 million and R&D of $2.4 million in the quarter. Cash and cash equivalents were $7.5 million at quarter end.
Management disclosed substantial doubt about the company’s ability to continue as a going concern. Based on current plans, cash resources are estimated to fund operations into, but not beyond, the third calendar quarter of 2026.
To bolster liquidity, Autonomix entered a $15.0 million equity purchase agreement with Lincoln Park and issued 261,932 commitment shares; no sales had occurred under this facility by September 30. The company also utilized its ATM program, selling 1,682,685 shares for approximately $2.6 million fiscal‑to‑date, including 378,425 shares for about $0.5 million in the quarter, and completed a July warrant inducement for roughly $2.5 million gross. Shares outstanding were 6,886,648 as of November 4, 2025.
Autonomix Medical, Inc. is a pre-revenue, clinical-stage medical device company advancing a catheter-based sensing and radiofrequency ablation platform. For the three months ended June 30, 2025, the company reported a net loss of $3.3 million (versus $2.7 million a year earlier), research and development expense of $1.6 million (up 67%), and general and administrative expense of $1.8 million. Cash totaled $8.6 million with working capital of $7.0 million as of June 30, 2025. Weighted average shares outstanding were 3,105,156, producing loss per share of $1.07. The company completed a 1-for-20 reverse stock split and raised financing including a November 2024 offering (gross ~$10.0 million; net proceeds ~$9.0 million) and ATM sales of 1,304,260 shares for net proceeds of ~$2.1 million.
The company reported positive early clinical results from its PoC 1 study with mean pain reduction of 59.2% among responders, no device-related serious adverse events, initiation of PoC 2 in June 2025, two issued U.S. patents, and an FDA pre-submission meeting that framed a path toward an EFS and potential De Novo approval target in 2028. Management discloses substantial doubt about going concern, estimating cash resources sufficient only into, but not beyond, the second calendar quarter of 2026 and forecasting an additional financing need of approximately $32–40 million to reach commercialization.